Why the study?
Left ventricular thrombus is typically managed with vitamin K antagonists, but data on the effectiveness and safety of DOACs remain limited and conflicting.
Do direct oral anticoagulants (DOACs) improve left ventricular thrombus resolution at 24 months compared to warfarin in patients with left ventricular thrombus?
Do direct oral anticoagulants (DOACs) improve left ventricular thrombus resolution at 24 months compared to warfarin in patients with left ventricular thrombus?
In this single-center retrospective cohort, DOAC therapy was independently associated with significantly higher rates of left ventricular thrombus resolution at 24 months and a comparable safety profile regarding bleeding and thromboembolism compared to warfarin.
Answers are grounded in this paper and cite their sources.
DOACs may be preferred for LVT resolution; leaves open confirmation in randomized trials.
Background and Aim: Left ventricular thrombus (LVT) is a common complication of myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF), typically managed with vitamin K antagonists (VKAs) for up to six months. However, data on direct oral anticoagulants (DOACs) for LVT treatment remain limited and conflicting. This study evaluates the effectiveness and safety of DOACs compared to warfarin for LVT resolution. Methods: We conducted a single-center retrospective cohort study of consecutive patients diagnosed with LVT from January 2010 to May 2024. The primary outcome was LVT resolution at 24 months. Safety outcomes included major bleeding and thromboembolic events. Diagnosis and follow-up were performed via echocardiography, with cardiac magnetic resonance and computed tomography as needed. Anticoagulant type, dose, duration, and concurrent antiplatelet therapy were at the treating physician’s discretion. Results: Among 171 patients (82.5% male, mean age 59.8 ± 14.7 years), 99 received DOACs and 72 received warfarin. LVT resolution was higher with DOACs (66.7% vs. 50%, HR 2.0, 95% CI 1.07–3.73, p = 0.029), with a trend toward faster thrombus resolution (185 vs. 220 days, p = 0.214) though statistically not significant. DOAC use remained an independent predictor of LVT resolution, regardless of antiplatelet use. Major bleeding (2.9%), thromboembolic events (5.3%), and mortality (5.3%) were similar between groups. Conclusions: DOAC therapy was associated with higher LVT resolution rates and a comparable safety profile to warfarin. Further randomized clinical trials are warranted to validate these findings.
No takes yet. Share an insight, caveat, or question.
Paiva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: